Skip NavigationSkip to Content
Return Return to Search Results

Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy

  1. Author:
    Krug, Karsten
    Jaehnig, Eric J
    Satpathy, Shankha
    Blumenberg, Lili
    Karpova, Alla
    Anurag, Meenakshi
    Miles, George
    Mertins, Philipp
    Geffen, Yifat
    Tang, Lauren C
    Heiman, David I
    Cao, Song
    Maruvka, Yosef E
    Lei, Jonathan T
    Huang, Chen
    Kothadia, Ramani B
    Colaprico, Antonio
    Birger, Chet
    Wang, Jarey
    Dou, Yongchao
    Wen, Bo
    Shi, Zhiao
    Liao, Yuxing
    Wiznerowicz, Maciej
    Wyczalkowski, Matthew A
    Chen, Xi Steven
    Kennedy, Jacob J
    Paulovich, Amanda G
    Thiagarajan,Mathangi
    Kinsinger, Christopher R
    Hiltke, Tara
    Boja, Emily S
    Mesri, Mehdi
    Robles, Ana I
    Rodriguez, Henry
    Westbrook, Thomas F
    Ding, Li
    Getz, Gad
    Clauser, Karl R
    Fenyö, David
    Ruggles, Kelly V
    Zhang, Bing
    Mani, D R
    Carr, Steven A
    Ellis, Matthew J
    Gillette, Michael A

  2. Author Address

    Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA., Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Institute for Systems Genetics and Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA., Department of Medicine and Genetics, Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, USA., Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Max Delbr 252;ck Center for Molecular Medicine in the Helmholtz Society and Berlin Institute of Health, Berlin, Germany., Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Department of Biological Sciences, Columbia University, New York, NY 10027, USA., Division of Biostatistics, Department of Public Health Science, University of Miami Miller School of Medicine, Miami, FL 33136, USA., Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Department of Molecular and Human Genetics, and Therapeutic Innovation Center, Baylor College of Medicine, Houston, TX 77030, USA., Poznan University of Medical Sciences, Poznan 61-701, Poland; International Institute for Molecular Oncology, 60-203 Poznan, Poland., Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA., Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD 20892, USA., Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02114, USA., Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY 10016, USA., Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. Electronic address: manidr@broadinstitute.org., Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. Electronic address: scarr@broad.mit.edu., Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: mjellis@bcm.edu., Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: gillette@broadinstitute.org.,
    1. Year: 2020
    2. Date: NOV 25
    3. Epub Date: 2020 11 16
  2. Journal: Cell
    1. 183
    2. 5
    3. Pages: 1436-+
  4. Type of Article: Article
  5. ISSN: 0092-8674
  1. Abstract:

    The integration of mass spectrometry-based proteomics with next-generation DNA and RNA sequencing profiles tumors more comprehensively. Here this "proteogenomics" approach was applied to 122 treatment-naive primary breast cancers accrued to preserve post-translational modifications, including protein phosphorylation and acetylation. Proteogenomics challenged standard breast cancer diagnoses, provided detailed analysis of the ERBB2 amplicon, defined tumor subsets that could benefit from immune checkpoint therapy, and allowed more accurate assessment of Rb status for prediction of CDK4/6 inhibitor responsiveness. Phosphoproteomics profiles uncovered novel associations between tumor suppressor loss and targetable kinases. Acetylproteome analysis highlighted acetylation on key nuclear proteins involved in the DNA damage response and revealed cross-talk between cytoplasmic and mitochondrial acetylation and metabolism. Our results underscore the potential of proteogenomics for clinical investigation of breast cancer through more accurate annotation of targetable pathways and biological features of this remarkably heterogeneous malignancy. Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.cell.2020.10.036
  3. PMID: 33212010
  4. View record in Web of Science®
  5. WOS: 000593203800022
  6. PII : S0092-8674(20)31400-8

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel